

Prevalence of Pharmaceutical Anti-Depressant Non-Medical Use in the United States

Joshua Black PhD

Alyssa Forber MS, Janetta Iwanicki MD, Richard Dart MD PhD

Rocky Mountain Poison & Drug Safety

RADARS® System

24 October 2021 – APHA Annual Meeting

Funding Disclosures

This work was performed by the Researched Abuse, Diversion and Addiction-Related Surveillance (RADARS[®]) System. The RADARS System operations are supported by subscriptions from pharmaceutical manufacturers, government and non-government agencies for surveillance, research, and reporting services. RADARS System is the property of Denver Health and Hospital Authority (DHHA), a political subdivision of the State of Colorado. Subscribers did not participate in conception, analysis, drafting, or review of this work.

This work was directly funded by DHHA.

No other competing conflicts of interest are declared.

Prevalence of Non-Medical Use of Antidepressants is Not Known

Non-medical use (NMU) of psychoactive drugs other than opioids, stimulants, and sedatives/tranquilizers is understudied.

Review of NMU of antidepressants found primarily case reports¹ and novel psychoactive substances are increasingly implicated for abuse².

Study Goal: Conduct descriptive study of prevalence of NMU of antidepressants in the US general population, describing reasons for NMU. Examine trends across COVID-19 pandemic.

Study Design and Methods

Study Design: Data Source Description

- Survey of Non-Medical Use of Prescription Drugs (NMURx) Program
 - Target population: All adults in the US
 - Sampled from an online commercial panel company
 - Non-probability sampling adjusted using calibration weights (raking)
 - Calibration conducted using both demographic and health characteristics
- Asks about use of multiple prescription drug classes, including antidepressants
 - Asks about detailed reason for use for each drug
- Key measures in survey shown to be valid³ and reliable⁴

Study Design: Sample Collection

- 120,000 participants collected in semi-annual waves across 2 years (30k per wave)
 - Pre-COVID period: 3rd quarter 2019, 1st quarter 2020
 - Closed 12 March 2020, 5 days before first US lockdown
 - During COVID period: 3rd quarter 2020, 1st quarter 2021
 - ~70-80% participation rate per wave
- Participants weighted per wave using 3 demographics (sex, age, region) and 2 health (smoking, limitation in activity)
- Data cleaning included careless response exclusions

Study Design: Drug Use Questions


- Respondents asked about NMU: “Have you used the prescription antidepressant below **in a way not directed by your healthcare provider** in the last 12 months?”
 - Citalopram, escitalopram, fluoxetine, sertraline, trazodone
 - Highest antidepressant retail dispensing circa 2019, 3rd quarter
- Respondents are asked follow-up on: “In the last 12 months, what are all the reasons you used [DRUG] in a way not directed by your healthcare provider?”
 - Reasons listed as check-all-that-apply; order randomized
- Use DAST-10 as proxy for problematic drug use

Study Design: Statistical Analysis

- Estimated number of adults and percentages
- 95% confidence intervals bootstrapped by resampling respondents
 - Respondents can return in different calendar years (~10% of antidepressant sample)
 - Adjusts CIs for correlated responses across calendar years
 - Formal statistical tests not conducted at this time; results only descriptive
- Estimates presented by period: Pre-COVID & During COVID

Results and Conclusions

Prevalence of Antidepressant NMU




From 3rd quarter 2020 to 1st quarter 2021...

- Estimated 41M adults used an antidepressant in the last 12 months for any reason (16% national prevalence)
- Among adults who used, 15.7% used non-medically (6.5M adults)

Among adults using non-medically...

- NMU of trazadone alone was the most frequent, though similar to those using sertraline, fluoxetine, or multiple drugs
- NMU of citalopram & escitalopram were smaller and similar

Characteristics of adults who NMU




Compared to adults who use as directed, adults who NMU are more likely to be/have...

- Male
- Younger
- From West vs Midwest
- Hispanic, Asian, or Black
- In substance use treatment
- Problematic drug use markers

Less likely to have...

- Anxiety or Depressive Disorder diagnosis

Trends in Use Over Time




Expect some seasonal variation, but lack of long-term data makes results only suggestive.

Adults who use as directed was mostly unchanged from prior to pandemic to during the pandemic.

Adults who non-medically used appeared to increase during the pandemic.

Reasons for NMU



- Use to treat anxiety and depression are most common (unsurprisingly)
- Other reasons for use are prevalent (>1M adults), including
 - Treating pain
 - Helping motivation
 - Helping stress
 - Giving energy
- Use to get high is uncommon
 - Consistent with low abuse potential studies
- Use to hurt oneself low
 - Huge increase during pandemic
- More people were using for all reasons during the pandemic

Strengths and Limitations

Strengths

- Nationally representative sample
- Validated control for composition bias
- Online data collection not impacted by pandemic restrictions

Limitations

- Only top 5 drugs by dispensing collected
 - Bias toward underestimated antidepressant use
- Repeat respondents ignored
 - Bias toward underestimated drug use
- Insufficient prior data to analyze numeric trends across pandemic
 - Results only descriptive/suggestive

Conclusions

- Descriptive study estimated 6.5M US adults non-medically use antidepressants throughout the year
- Characteristics indicate concurrent problematic drug use and unrecognized mental health conditions among adults who NMU
- Increased NMU in pandemic period, but no increase in use as directed, suggests mental health needs going untreated by professionals
 - Nearly doubling use to harm oneself particularly concerning
- Residual pandemic challenges (economic instability, restricted healthcare) could mean NMU continues well beyond the immediate pandemic

References

1. Evans EA, Sullivan MA. Abuse and misuse of antidepressants. *Subst Abuse Rehabil.* 2014 Aug 14;5:107-20. doi: 10.2147/SAR.S37917. PMID: 25187753; PMCID: PMC4140701.
2. Schifano F, Chiappini S, Corkery JM, Guirguis A. Abuse of Prescription Drugs in the Context of Novel Psychoactive Substances (NPS): A Systematic Review. *Brain Sci.* 2018 Apr 22;8(4):73. doi: 10.3390/brainsci8040073. PMID: 29690558; PMCID: PMC5924409.
3. Black JC, Rockhill K, Forber A, Amioka E, May KP, Haynes CM, Dasgupta N, Dart RC. An Online Survey for Pharmacoepidemiological Investigation (Survey of Non-Medical Use of Prescription Drugs Program): Validation Study. *J Med Internet Res.* 2019 Oct 25;21(10):e15830. doi: 10.2196/15830. PMID: 31654568; PMCID: PMC6914238.
4. Black JC, Forber A, Severtson SG, Rockhill K, May KP, Amioka E, Schwarz J, Iwanicki J, Dart RC. Drug product dispensing and estimates of use in a general population survey as a signal detection problem. *Pharmacoepidemiol Drug Saf.* 2021 Aug;30(8):1132-1139. doi: 10.1002/pds.5260. Epub 2021 May 10. PMID: 33931917.

Thank you!


Joshua Black, PhD

joshua.black@rmpds.org

RADARS® System

Backup

Coverage



Respondents

Source: RADARS® System Survey of Non-Medical Use of Prescription Drugs Program
Surveillance period: 2020